Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- DRRX
- Price
- 0.69
- Stock movement up
- +0.04 (5.38%)
- Company name
- Durect Corporation
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 21.49M
- Ent value
- 35.25M
- Price/Sales
- 2.50
- Price/Book
- 17.66
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -8.04%
- 1 year return
- -61.12%
- 3 year return
- -50.43%
- 5 year return
- -50.51%
- 10 year return
- -31.17%
Last updated: 2025-08-27
DIVIDENDS
DRRX does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.50 |
| Price to Book | 17.66 |
| EV to Sales | 4.10 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 31.05M |
| EPS (TTM) | -0.55 |
| FCF per share (TTM) | -0.74 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 8.59M |
| Gross profit (TTM) | 6.78M |
| Operating income (TTM) | -19.34M |
| Net income (TTM) | -17.07M |
| EPS (TTM) | -0.55 |
| EPS (1y forward) | -0.70 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 78.87% |
| Operating margin (TTM) | -225.06% |
| Profit margin (TTM) | -198.62% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 9.09M |
| Net receivables | 1.02M |
| Total current assets | 14.43M |
| Goodwill | 6.17M |
| Intangible assets | 0.00 |
| Property, plant and equipment | 3.19M |
| Total assets | 24.07M |
| Accounts payable | 498.00K |
| Short/Current long term debt | 13.74M |
| Total current liabilities | 20.21M |
| Total liabilities | 22.85M |
| Shareholder's equity | 1.22M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -21.89M |
| Capital expenditures (TTM) | 1.03M |
| Free cash flow (TTM) | -22.93M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -1402.55% |
| Return on Assets | -70.93% |
| Return on Invested Capital | -119.37% |
| Cash Return on Invested Capital | -160.35% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.64 |
| Daily high | 0.69 |
| Daily low | 0.63 |
| Daily Volume | 25K |
| All-time high | 158.13 |
| 1y analyst estimate | 2.50 |
| Beta | 0.84 |
| EPS (TTM) | -0.55 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| DRRX | S&P500 | |
| Current price drop from All-time high | -99.56% | -3.04% |
| Highest price drop | -99.68% | -56.47% |
| Date of highest drop | 27 May 2025 | 9 Mar 2009 |
| Avg drop from high | -83.34% | -11.04% |
| Avg time to new high | 1554 days | 12 days |
| Max time to new high | 6190 days | 1805 days |
COMPANY DETAILS
Marketcap
21.49M
Marketcap category
Small-cap
Description
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment of patients with metabolic dysfunction-associated steatohepatitis. The company also offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; PERSERIS, an injectable suspension for the treatment of schizophrenia in adults; and Methydur to treat attention deficit hyperactivity disorder. It has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Employees
13
Website
Investor relations
-
SEC filings
CEO
James E. Brown
Country
USA
City
Cupertino
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner